keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/28535004/peroxiredoxin-5-overexpression-enhances-tumorigenicity-and-correlates-with-poor-prognosis-in-gastric-cancer
#1
Bokyung Kim, Yeon Soo Kim, Hye-Mi Ahn, Hyo Jin Lee, Min Kyu Jung, Hyun Yong Jeong, Dong Kyu Choi, Jun Hyeog Lee, Sang-Rae Lee, Jin Man Kim, Dong-Seok Lee
Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Despite the advanced surgical resection techniques and anticancer drugs currently available to treat early stage gastric cancer, the prognosis of patients with gastric cancer remains poor. The epithelial to mesenchymal transition (EMT) is an important process for the initiation of tumorigenesis. Recent studies suggested that reactive oxygen species (ROS) can promote cell migration and invasion. Thus, an imbalance of redox homeostasis can result in cancer cells exhibiting EMT properties...
May 19, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28534824/isorhynchophylline-a-potent-plant-alkaloid-induces-apoptotic-and-anti-metastatic-effects-in-human-hepatocellular-carcinoma-cells-through-the-modulation-of-diverse-cell-signaling-cascades
#2
Hanwool Lee, Seung Ho Baek, Jong Hyun Lee, Chulwon Kim, Jeong-Hyeon Ko, Seok-Geun Lee, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Woong Mo Yang, Jae-Young Um, Gautam Sethi, Kwang Seok Ahn
Isorhynchophylline (Rhy) is an active pharmacological component of Uncaria rhynchophylla that has been reported previously to exert significant antihypertensive and neuroprotective effects. However, very little is known about its potential anti-cancer activities. This study was carried out to evaluate the anticancer effects of Rhy against various human carcinoma cell lines. We found that Rhy exhibited substantial cytotoxic effect against human hepatocellular carcinoma HepG2 cells when compared with other human carcinoma cell lines including those of lung, pancreas, prostate, head and neck, breast, multiple myeloma, brain and renal cell carcinoma...
May 19, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28534688/coexisting-prostate-cancer-and-diabetes-mellitus-implications-for-patient-outcomes-and-care
#3
Nina J Karlin, Shailja B Amin, Patricia M Verona, Heidi E Kosiorek, Curtiss B Cook
OBJECTIVE: To investigate how diabetes mellitus (DM) impacts short-term overall survival for patients with prostate cancer and to examine how prostate cancer impacts glycemic control in DM. METHODS: Patients with DM and prostate cancer newly diagnosed from 2007-2014 were identified from the institutional cancer registry and matched to patients with prostate cancer but no DM according to age and year of prostate cancer diagnosis. RESULTS: The study included 276 cases and 276 controls; the mean age was 72 years, most (93%) were white, the most common Gleason score (52%) was 7, and the majority (56%) were tumor stage II...
May 23, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28534184/evaluation-of-cardiovascular-ischemic-event-rates-in-dasatinib-treated-patients-using-standardized-incidence-ratios
#4
Giuseppe Saglio, Philipp le Coutre, Jorge Cortes, Jiří Mayer, Philip Rowlings, François-Xavier Mahon, Glenn Kroog, Kyna Gooden, Milayna Subar, Neil P Shah
With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY)...
May 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28533151/low-rates-of-androgen-deprivation-therapy-use-with-salvage-radiation-therapy-in-patients-with-prostate-cancer-after-radical-prostatectomy
#5
David D Yang, Vinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, Shelby A Labe, Marie E Vastola, Ninjin Boldbaatar, Martin T King, Neil E Martin, Peter F Orio, Tni K Choueiri, Quoc-Dien Trinh, Robert B Den, Daniel E Spratt, Karen E Hoffman, Felix Y Feng, Paul L Nguyen
OBJECTIVE: The RTOG 9601 and GETUG-AFU 16 randomized controlled trials demonstrated that the addition of androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) improves progression-free and, for RTOG 9601, overall survival. We examined national trends in the use of ADT with SRT. MATERIALS AND METHODS: Of the 484,009 patients in the National Cancer Database from 2004 to 2012 with localized or locally advanced prostate cancer treated with radical prostatectomy (RP), 4,200 men received SRT (≥6mo after surgery)...
May 19, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28532400/oligometastases-from-prostate-cancer-local-treatment-with-stereotactic-body-radiotherapy-sbrt
#6
Gregor Habl, Christoph Straube, Kilian Schiller, Marciana Nona Duma, Markus Oechsner, Kerstin A Kessel, Matthias Eiber, Markus Schwaiger, Hubert Kübler, Jürgen E Gschwend, Stephanie E Combs
BACKGROUND: The impact of local tumor ablative therapy in oligometastasized prostate cancer (PC) is still under debate. To gain data for this approach, we evaluated oligometastasized PC patients receiving stereotactic body radiotherapy (SBRT) to bone metastases. METHODS: In this retrospective study, 15 oligometastasized PC patients with a total of 20 bone metastases were evaluated regarding biochemical progression-free survival (PSA-PFS), time to initiation of ADT, and local control rate (LCR)...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28531567/impact-of-body-composition-parameters-on-clinical-outcomes-in-patients-with-metastatic-castrate-resistant-prostate-cancer-treated-with-docetaxel
#7
Samantha J Cushen, Derek G Power, Kevin P Murphy, Ray McDermott, Brendan T Griffin, Marvin Lim, Louise Daly, Peter MacEneaney, Kathleen O' Sullivan, Carla M Prado, Aoife M Ryan
BACKGROUND: Body composition may influence clinical outcomes of certain chemotherapeutic agents. We examined the prognostic significance of skeletal muscle mass and adipose tissue on docetaxel toxicity and overall survival in patients with metastatic castrate resistant prostate cancer (mCRPC). METHODS: A retrospective review of patients medical records with mCRPC, treated with docetaxel was conducted. Body composition parameters (skeletal muscle mass, muscle attenuation [MA], visceral and subcutaneous adipose tissue) were measured at L3 by computed tomography (CT) and defined using previously established cut points...
June 2016: Clinical Nutrition ESPEN
https://www.readbyqxmd.com/read/28531102/nanoparticles-as-theranostic-vehicles-in-experimental-and-clinical-applications-focus-on-prostate-and-breast-cancer
#8
REVIEW
Jörgen Elgqvist
Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates...
May 20, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28530220/presence-of-invasive-cribriform-or-intraductal-growth-at-biopsy-outperforms-percentage-grade-4-in-predicting-outcome-of-gleason-score-3-4-7-prostate-cancer
#9
Charlotte F Kweldam, Intan P Kümmerlin, Daan Nieboer, Ewout W Steyerberg, Chris H Bangma, Luca Incrocci, Theodorus H van der Kwast, Monique J Roobol, Geert J van Leenders
Relative increase of grade 4 and presence of invasive cribriform and/or intraductal carcinoma have individually been associated with adverse outcome of Gleason score 7 (GS 7) prostate cancer. The objective of this study was to investigate the relation of Gleason grade 4 tumor percentage (%GG4) and invasive cribriform and/or intraductal carcinoma in GS 3+4=7 prostate cancer biopsies. We reviewed 1031 prostate cancer biopsies from the European Randomized Study of Screening for Prostate Cancer. In total 370 men had G3+4=7...
May 19, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28529582/angiotensin-ii-receptor-blockers-induce-autophagy-in-prostate-cancer-cells
#10
Yunseo Woo, Yu-Jin Jung
Angiotensin II receptor blockers (ARBs) are anti-hypertensive drugs that competitively inhibit the binding of angiotensin II to its receptor, resulting in blood vessel dilation and the reduction of blood pressure. These antagonists are also known as sartans, and are a group of pharmaceuticals that possess tetrazole or imidazole groups. In the present study, the anticancer and antimetastatic effects of the ARBs fimasartan, losartan, eprosartan and valsartan on the human prostate cancer PC-3, DU-145 and LNCap-LN3 cell lines were investigated in vitro...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28529549/abiraterone-acetate-and-prednisone-in-chemotherapy-na%C3%A3-ve-prostate-cancer-patients-rationale-evidence-and-clinical-utility
#11
REVIEW
E David Crawford, Neal D Shore, Daniel P Petrylak, Celestia S Higano, Charles J Ryan
Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate is the oral prodrug of abiraterone, a specific CYP17 inhibitor that blocks androgen biosynthesis within the adrenal glands, testes and tumor microenvironment. In a phase III trial of men with asymptomatic or minimally symptomatic, chemotherapy-naïve mCRPC, treatment with oral abiraterone acetate plus prednisone led to a statistically significant improvement in the co-primary endpoints of overall survival and radiographic progression-free survival when compared with placebo plus prednisone...
May 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28529548/docetaxel-in-prostate-cancer-a-familiar-face-as-the-new-standard-in-a-hormone-sensitive-setting
#12
REVIEW
Javier Puente, Enrique Grande, Ana Medina, Pablo Maroto, Nuria Lainez, Jose Angel Arranz
The increasing knowledge of prostate cancer is leading to many questions about its natural history and to reconsider conventional therapeutic strategies. Androgen ablation therapy has been the standard therapy in the advanced setting. Although docetaxel has demonstrated increased survival in patients with metastatic prostate cancer who had progressed to hormone treatments, due to its potential toxicity the role of chemotherapy has been relegated to patients who were symptomatic or who had high tumor burden...
May 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28529342/circulating-tumor-cells-and-serum-levels-of-mmp-2-mmp-9-and-vegf-as-markers-of-the-metastatic-process-in-patients-with-high-risk-of-metastatic-progression
#13
Marketa Skerenova, Veronika Mikulova, Otakar Capoun, Tomas Zima, Petra Tesarova
BACKGROUND AND AIMS: Metastases are a severe complication in cancer patients and biomarkers predicting their progression are still lacking for specific groups of patients. HER2 positive breast cancer (HER2 BC) patients on trastuzumab therapy are at risk of the development of unpredictable and often fatal central nervous system (CNS) metastases and castration resistant prostate cancer (CRPC) patients urgently need a marker of disease progression during therapy. Proposed metastatic markers: circulating tumor cells (CTC), serum levels of matrix metalloproteinase 2 (MMP-2), 9 (MMP-9) and vascular endothelial growth factor (VEGF) were prospectively studied to confirm their utility in these two narrowly defined groups of cancer patients...
May 16, 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/28528448/prostate-cancer-related-anxiety-in-long-term-survivors-after-radical-prostatectomy
#14
Valentin H Meissner, Kathleen Herkommer, Birgitt Marten-Mittag, Jürgen E Gschwend, Andreas Dinkel
PURPOSE: Knowledge of the psychological distress of long- and very long-term (>10 years) prostate cancer (PC) survivors is limited. This study intended to examine the parameters influencing anxiety related to prostate-specific antigen (PSA) and PC in long-term survivors after radical prostatectomy. METHODS: We surveyed 4719 PC survivors from the German multicenter prospective database "Familial Prostate Cancer." We evaluated the association of PC-related anxiety (MAX-PC) with sociodemographic characteristics, family history of PC, global health status/quality of life (EORTC QLQ-C30), depression and anxiety (PHQ-2; GAD-2), latest PSA level, time since radical prostatectomy, and current therapy...
May 21, 2017: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/28526604/extramural-perineural-invasion-in-pt3-and-pt4-rectal-adenocarcinoma-as-prognostic-factor-after-preoperative-chemoradiotherapy
#15
Leonardo S Lino-Silva, Rosa A Salcedo-Hernández, Alejandro España-Ferrufino, Erika B Ruiz-García, Miguel Ruiz-Campos, Alberto M León-Takahashi, Abelardo Meneses-García
Perineural invasion (PNI) is widely studied in malignant tumors, and its prognostic significance is well demonstrated in the head and neck and prostate carcinomas, but its significance in rectal cancer is controversial. Most studies have focused on evaluating mural PNI (mPNI); however, extramural PNI (ePNI) may influence the prognosis after rectal cancer resection. We evaluated the prognostic value of ePNI compared with mPNI and with non-PNI, in rectal resections after preoperative chemoradiotherapy in 148 patients with pT3 and pT4 rectal carcinomas...
May 16, 2017: Human Pathology
https://www.readbyqxmd.com/read/28526418/prevalence-of-measurable-disease-in-metastatic-castration-resistant-prostate-cancer
#16
Guru Sonpavde, Ankit Madan, Mary K Baker, Jori E May, Gurudatta Naik, Sejong Bae
BACKGROUND: Because of the low historical prevalence of measurable disease in metastatic castration-resistant prostate cancer (mCRPC), phase II trials have used prostate-specific antigen (PSA) and bone scan changes as primary end points. Frequent whole-body imaging and improved computed tomography technology currently identify measurable disease more frequently, warranting consideration of objective response as a major end point. PATIENTS AND METHODS: Data from reported phase III trials of mCRPC were analyzed...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28525906/copy-number-variations-of-circulating-cell-free-dna-in-urothelial-carcinoma-of-the-bladder-patients-treated-with-radical-cystectomy-a-prospective-study
#17
Armin Soave, Felix K-H Chun, Timo Hillebrand, Michael Rink, Lars Weisbach, Bettina Steinbach, Margit Fisch, Klaus Pantel, Heidi Schwarzenbach
The aim of the present study was to establish a rapid profiling method using multiplex ligation-dependent probe amplification (MLPA) and characterize copy number variations (CNV) in circulating, cell-free DNA (cfDNA) in 85 urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). MLPA was tested for the use of cfDNA extracted from serum and plasma by various commercial extraction kits. Eighteen probes served as reference to control denaturation, ligation and amplification efficiency...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28525899/the-prognostic-value-of-long-noncoding-rnas-in-prostate-cancer-a-systematic-review-and-meta-analysis
#18
Weijie Ma, Xi Chen, Lu Ding, Jianhong Ma, Wei Jing, Tian Lan, Haseeb Sattar, Yongchang Wei, Fuling Zhou, Yufeng Yuan
The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, we conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into our analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS) (HR = 1...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28525372/overexpression-of-a-novel-candidate-oncogene-kif14-correlates-with-tumor-progression-and-poor-prognosis-in-prostate-cancer
#19
Yixiang Zhang, Yeqing Yuan, Pei Liang, Zhaoxia Zhang, Xiaojing Guo, Ligang Xia, Yingying Zhao, Xing-Sheng Shu, Shengkun Sun, Ying Ying, Yingduan Cheng
Prostate cancer (PCa) is the second leading cause of death from cancer in men. The mechanism underlying tumorigenesis and development of PCa is largely unknown. Here, we identified Kinesin family member 14 (KIF14) as a novel candidate oncogene in PCa. We found that KIF14 was overexpressed in multiple PCa cell lines and primary PCa tissues. Knockdown of KIF14 in DU145 and PC3 prostate cancer cells suppressed cell proliferation, induced cell cycle arrest and apoptosis. Transcriptome analysis by RNA-sequencing demonstrated that KIF4 suppression led to transcriptional changes of genes involved in p53 and TGF-beta signaling pathway...
May 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28523407/heterogeneous-oncologic-outcomes-according-to-surgical-pathology-in-high-risk-prostate-cancer-implications-for-better-risk-stratification-and-preoperative-prediction-of-oncologic-outcomes
#20
Seung-Kwon Choi, Myungsun Shim, Myong Kim, Myungchan Park, Sangmi Lee, Cheryn Song, Hyung-Lae Lee, Hanjong Ahn
PURPOSE: To evaluate the better risk stratification based on surgical pathology, and to predict oncologic outcomes after radical prostatectomy (RP) with a better scoring system in high-risk prostate cancer (PCa) patients. METHODS: We evaluated high-risk PCa patients (PSA >20 ng/ml, ≥cT3a, or Gleason score 8-10) who underwent RP between 2007 and 2013 at our institute. We classified patients into three groups according to their pathologic outcomes: favorable (pT2, Gleason score ≤7, and node negative), intermediate (specimen-confined disease (pT2-3a, node negative PCa with negative surgical margins) but not in the favorable group), and unfavorable (the remaining patients)...
May 18, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"